Five indications added to Pharmacy First prescribing scheme
Some pharmacists in England can now prescribe drugs for acne, migraines, scabies, ear infections, and rhinitis under the Pharmacy First scheme.
Could UK clinical trial revamp unlock closer ties with Canad...
Two senior figures in Canada's life science sector have said they see scope for greater collaboration with the UK following clinical trial reforms.
Reviews underway of first drug for rare disease MOGAD
Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.
Bayer moves Hyrnuo into frontline lung cancer treatment
Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
NICE says no to Gilead's lenacapavir for HIV PrEP
NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access
10th Complement-Based Drug Development Summit
Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications
Better Antifibrotic Decisions Through Cross-Organ Insights
The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development